Development of an inhalation chamber and a dry powder inhaler device for administration of pulmonary medication in animal model

Drug Development and Industrial Pharmacy

Volumn 38, Issue 2, 2012, Pages 171-179

  Sinha, Biswadip ^a   Mukherjee, Biswajit ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Aerosols; Animal model; Dry powder inhaler; in vivo lung deposition; Inhalation device; Pulmonary drug delivery

Indexed keywords

VORICONAZOLE;

AERODYNAMIC DIAMETER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATMOSPHERIC PRESSURE; DRUG DEPOSITION; DRUG SCREENING; DRUG TISSUE LEVEL; EQUIPMENT DESIGN; INHALATION SPACER; MEDICAL NEBULIZER; NONHUMAN; POWDER INHALER;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; FEMALE; MALE; MICE; MODELS, ANIMAL; PULMONARY MEDICINE;

EID: 84255182796     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.592532     Document Type: Article

References (24)

1. Watts AB, McConville JT, Williams RO 3rd. (2008). Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm, 34:913-922.
2. Adi H,Young PM,Chan H-K, Salama R, Traini D. (2010). Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm, 36:119-126.
3. Son YJ, McConville JT. (2008). Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm, 34:948-959.
4. Overhoff KA, Clayborough R, Crowley M. (2008). Review of the TAIFUN multidose dry powder inhaler technology. Drug Dev Ind Pharm, 34:960-965.
5. Blagoeva PM, Mircheva TJ, Atanassova RB, Atanassov BT. (1997). Genotoxic changes in the pulmonary alveolar macrophages of mice, rats and hamsters treated with tobacco smoke. J Cancer Res Clin Oncol, 123:253-258. (Pubitemid 27230900)
6. Fukayama MY, Easterday OD, Serafino PA, Renskers KJ, North-Root H, Schrankel KR. (1999). Subchronic inhalation studies of complex fragrance mixtures in rats and hamsters. Toxicol Lett, 111:175-187.
7. McConville JT, Williams RO 3rd, Carvalho TC, Iberg AN, Johnston KP, Talbert RL et al. (2005). Design and evaluation of a restraintfree small animal inhalation dosing chamber. Drug Dev Ind Pharm, 31:35-42. (Pubitemid 40170586)
8. Raeburn D, Underwood SL, Villamil ME. (1992). Techniques for drug delivery to the airways, and the assessment of lung function in animal models. J Pharmacol Toxicol Methods, 27:143-159.
9. Negishi T, Nishimura I. (1993). Dust inhalation system for small laboratory animals. Jikken Dobutsu, 42:159-168.
10. Kaur J, Muttil P, Verma RK, Kumar K, Yadav AB, Sharma R et al. (2008). A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci, 34:56-65.
11. Nadithe V, Rahamatalla M, Finlay WH, Mercer JR, Samuel J. (2003). Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J Pharm Sci, 92:1066-1076.
12. Bivas-Benita M, Zwier R, Junginger HE, Borchard G. (2005). Noninvasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm, 61:214-218. (Pubitemid 41427629)
13. Codrons V, Vanderbist F, Verbeeck RK, Arras M, Lison D, Préat V et al. (2003). Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci, 92:938-950. (Pubitemid 36523439)
14. Warheit DB, Brock WJ, Lee KP, Webb TR, Reed KL. (2005).comparative pulmonary toxicity inhalation and instillation studies with different TiO2 particle formulations: impact of surface treatments on particle toxicity. Toxicol Sci, 88:514-524. (Pubitemid 41672159)
15. Warheit DB, Webb TR, Reed KL, Hansen JF, Kennedy GL Jr. (2003). Four-week inhalation toxicity study in rats with nylon respirable fibers: rapid lung clearance. Toxicology, 192:189-210. (Pubitemid 37311411)
16. Sumner SC, Asgharian B, Moore TA, Parkinson HD, Bobbitt CM, Fennell TR. (2003). Characterization of metabolites and disposition of tertiary amyl methyl ether in male F344 rats following inhalation exposure. J Appl Toxicol, 23:411-417. (Pubitemid 37461716)
17. Cannon WC, Blanton EF, McDonald KE. (1983). The flow-past chamber: an improved nose-only exposure system for rodents. Am Ind Hyg Assoc J, 44:923-928. (Pubitemid 14177443)
18. McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Frei BL, Burgess DS et al. (2006). Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res, 23:901-911. (Pubitemid 43781398)
19. Holt J. 2010. MMAD & GSD Calculator for Andersen Cascade Impactors (ACI) [Online]. Available: http://www.mmadcalculator.com/andersen-impactor-mmad. html [Accessed 1st Sep 2010].
20. Buchanan CM,Buchanan NL,Edgar KJ & Ramsey MG. (2007). Solubilty and dissolution studies of antifungal drug: hydroxybutenyl-beta-cyclodextrin complexes. Cellulose, 14:35-47. (Pubitemid 46486879)
21. Tolman JA, Williams RO. (2010). Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev. Ind. Pharm., 36:1-30.
22. Thompson PJ. (1998). Drug delivery to the small airways. Am J Respir Crit Care Med, 157:S199-S202. (Pubitemid 28232585)
23. Ren Y, Yu C, Meng K, Tang X. (2008). Influence of formulation and preparation process on ambroxol hydrochloride dry powder inhalation characteristics and aerosolization properties. Drug Dev Ind Pharm, 34:984-991.
24. Boshhiha AM, Urbanetz NA. (2009). Influence of carrier surface fines on dry powder inhalation formulations. Drug Dev Ind Pharm, 35:904-916.